Abstract
Levodopa remains the gold standard for treating Parkinson’s disease, but there has long been controversy about this drug’s potential to exert toxic effects on nigral cells, thereby accelerating disease progression. William Weiner evaluates the evidence and explores the implications of this debate for interpreting research data.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
